These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 11828353)

  • 21. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer intervention. Involving the patient in early detection and treatment.
    Wilt TJ; Partin MR
    Postgrad Med; 2003 Oct; 114(4):43-9; quiz 50. PubMed ID: 14587206
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer.
    Wilt TJ; Brawer MK
    J Urol; 1994 Nov; 152(5 Pt 2):1910-4. PubMed ID: 7523736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of Prostate Cancer Morbidity and Mortality: Primary Prevention and Early Detection.
    Barry MJ; Simmons LH
    Med Clin North Am; 2017 Jul; 101(4):787-806. PubMed ID: 28577627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expectant management with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2002; 7(5):175-9. PubMed ID: 12644212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial.
    Bill-Axelson A; Holmberg L; Filén F; Ruutu M; Garmo H; Busch C; Nordling S; Häggman M; Andersson SO; Bratell S; Spångberg A; Palmgren J; Adami HO; Johansson JE;
    J Natl Cancer Inst; 2008 Aug; 100(16):1144-54. PubMed ID: 18695132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Watchful waiting as a treatment option for localized prostate cancer in the PSA era.
    Kakehi Y
    Jpn J Clin Oncol; 2003 Jan; 33(1):1-5. PubMed ID: 12604715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.
    Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P
    Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
    Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
    Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elderly and prostate cancer screening.
    Stamatiou KN
    Urol J; 2011; 8(2):83-7. PubMed ID: 21656465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of treatment of patients with prostate cancer initially managed with surveillance: results from The CaPSURE database. Cancer of the Prostate Strategic Urological Research Endeavor.
    Koppie TM; Grossfeld GD; Miller D; Yu J; Stier D; Broering JM; Lubeck D; Henning JM; Flanders SC; Carroll PR
    J Urol; 2000 Jul; 164(1):81-8. PubMed ID: 10840429
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.
    Loeb S; Zhou Q; Siebert U; Rochau U; Jahn B; Mühlberger N; Carter HB; Lepor H; Braithwaite RS
    Eur Urol; 2017 Dec; 72(6):899-907. PubMed ID: 28844371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with treatment received by men diagnosed with prostate cancer in Queensland, Australia.
    Baade PD; Youlden DR; Gardiner RA; Ferguson M; Aitken JF; Yaxley J; Chambers SK
    BJU Int; 2012 Dec; 110(11 Pt B):E712-9. PubMed ID: 23017157
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Team.
    Fleming C; Wasson JH; Albertsen PC; Barry MJ; Wennberg JE
    JAMA; 1993 May; 269(20):2650-8. PubMed ID: 8487449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary Care Physicians Beliefs about Prostate-Specific Antigen Evidence Uncertainty, Screening Efficacy, and Test Use.
    Ross LE; Hall IJ; Howard DL; Rim SH; Richardson LC
    J Natl Med Assoc; 2018 Oct; 110(5):491-500. PubMed ID: 30129508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis, management and screening of early localised prostate cancer.
    Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
    Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.